Boston Scientific Corp Files 8-K for Regulation FD Disclosure
Ticker: BSX · Form: 8-K · Filed: Nov 7, 2024 · CIK: 885725
| Field | Detail |
|---|---|
| Company | Boston Scientific CORP (BSX) |
| Form Type | 8-K |
| Filed Date | Nov 7, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, regulation-fd
Related Tickers: BSX
TL;DR
BSX filed an 8-K for a Reg FD disclosure, no new material info detailed.
AI Summary
On November 7, 2024, Boston Scientific Corporation (BSX) filed an 8-K to report a Regulation FD Disclosure. The filing does not contain specific financial figures or new material events beyond the reporting of the disclosure itself.
Why It Matters
This filing indicates Boston Scientific is making a public disclosure under Regulation FD, ensuring all investors receive the same material information simultaneously.
Risk Assessment
Risk Level: low — The filing is a standard procedural disclosure and does not contain information that would immediately impact the company's risk profile.
Key Players & Entities
- Boston Scientific Corporation (company) — Registrant
- BSX (company) — Ticker Symbol
- November 7, 2024 (date) — Filing Date
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure made by Boston Scientific Corporation on November 7, 2024.
What specific material information is disclosed in this filing?
This filing itself does not detail the specific material information being disclosed under Regulation FD; it only serves as notification of the disclosure.
When was this 8-K filed?
This 8-K was filed on November 7, 2024.
What is the company's principal business address?
The company's principal business address is 300 Boston Scientific Way, Marlborough, Massachusetts 01752-1234.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 489 words · 2 min read · ~2 pages · Grade level 14 · Accepted 2024-11-07 07:00:47
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value per share BSX New York Stock
Filing Documents
- bsx-20241107.htm (8-K) — 25KB
- 0000885725-24-000075.txt ( ) — 184KB
- bsx-20241107.xsd (EX-101.SCH) — 3KB
- bsx-20241107_def.xml (EX-101.DEF) — 15KB
- bsx-20241107_lab.xml (EX-101.LAB) — 27KB
- bsx-20241107_pre.xml (EX-101.PRE) — 16KB
- bsx-20241107_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On November 7, 2024, Boston Scientific Corporation (the "Company") announced that it is resuming the AVANT GUARD clinical trial studying a new population of drug-nave patients with persistent atrial fibrillation. The decision to resume enrollments in the trial was made following an assessment of observations within the trial and in conjunction with the study's data monitoring committee. The information contained in Item 7.01 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 7, 2024 BOSTON SCIENTIFIC CORPORATION By: /s/ Susan Thompson Susan Thompson Vice President, Chief Corporate Counsel and Assistant Secretary